| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.ATV.19.9.2226 |
| P698 | PubMed publication ID | 10479666 |
| P2093 | author name string | Anderson JW | |
| Bridges SR | |||
| Gowri MS | |||
| Van der Westhuyzen DR | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2226-2233 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. | |
| P478 | volume | 19 |
| Q35994373 | A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients. |
| Q38741489 | Advanced glycation of high-density lipoprotein and the functionality of aldosterone release in type 2 diabetes |
| Q46773060 | Aerobic exercise training improves the role of high-density lipoprotein antioxidant and reduces plasma lipid peroxidation in type 2 diabetes mellitus |
| Q36625116 | Alterations in lipoprotein defense against oxidative stress in metabolic syndrome |
| Q36955395 | Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis |
| Q35919274 | Anti-inflammatory properties of HDL. |
| Q41115717 | Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit |
| Q51776269 | ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. |
| Q92496091 | Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice |
| Q36647735 | Association of dietary vitamin C and e intake and antioxidant enzymes in type 2 diabetes mellitus patients |
| Q35944789 | Associations of Circulating Oxidized LDL and Conventional Biomarkers of Cardiovascular Disease in a Cross-Sectional Study of the Navajo Population |
| Q37172727 | Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies |
| Q43664426 | Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control |
| Q46504504 | Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. |
| Q37280331 | Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial |
| Q45281586 | Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. |
| Q35008823 | Detection of oxidized high-density lipoprotein |
| Q34107633 | Dietary fiber prevents carbohydrate-induced hypertriglyceridemia |
| Q34727869 | Dysfunctional high-density lipoprotein |
| Q37761073 | Dysfunctional high-density lipoprotein and atherosclerosis |
| Q38089207 | Effect of lipid-modifying therapies on the functional quality of high-density lipoproteins: implications for drug development. |
| Q39178456 | Extra-virgin olive oil consumption reduces the age-related decrease in HDL and paraoxonase 1 anti-inflammatory activities |
| Q34554267 | HDL and arteriosclerosis: beyond reverse cholesterol transport |
| Q34055877 | Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review |
| Q37243883 | High-carbohydrate diets affect the size and composition of plasma lipoproteins in hamsters (Mesocricetus auratus). |
| Q36562264 | High-density lipoprotein: is it always atheroprotective? |
| Q36611036 | High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. |
| Q34187954 | Impact of serum amyloid A on high density lipoprotein composition and levels |
| Q37015961 | Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia |
| Q37707402 | Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target? |
| Q83094731 | Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation |
| Q57182351 | Linking diabetes and atherosclerosis |
| Q35137994 | Lipid profile of type 2 diabetic and hypertensive patients in the jamaican population |
| Q39471135 | Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients; Relationship to glycemic control and coronary heart disease |
| Q35203793 | Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment |
| Q51347008 | Low normal free T4 confers decreased high-density lipoprotein antioxidative functionality in the context of hyperglycaemia. |
| Q33643266 | Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes |
| Q36587579 | Mechanisms of disease: proatherogenic HDL--an evolving field |
| Q36684197 | Modifying the anti-inflammatory effects of high-density lipoprotein |
| Q37806960 | Oxidative mechanisms and atherothrombotic cardiovascular disease |
| Q33554184 | Oxidative risk for atherothrombotic cardiovascular disease |
| Q95823849 | PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago |
| Q45943400 | Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy. |
| Q35088129 | Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL. |
| Q33996892 | Reverse cholesterol transport in diabetes mellitus |
| Q42921285 | Risk factors for cardiovascular disease in women with diabetes |
| Q37385859 | Serum Lipoprotein (a) Levels in Black South African Type 2 Diabetes Mellitus Patients |
| Q36497033 | Serum arylesterase and paraoxonase activity in patients with chronic hepatitis |
| Q36735598 | Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins |
| Q42376634 | The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation |
| Q87548200 | The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts myocardial injury following elective percutaneous coronary intervention |
| Q83302200 | The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in beta-thalassemia/Hb E |
| Q37778848 | The versatility of HDL: a crucial anti-inflammatory regulator. |
| Q49689988 | Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions |
| Q43787217 | Vascular effects of estrogen in type II diabetic postmenopausal women |
| Q33907770 | Whole grain foods and heart disease risk |
| Q35124783 | Whole grains protect against atherosclerotic cardiovascular disease |
| Q37119301 | Why is HDL functionally deficient in type 2 diabetes? |
Search more.